Pratia Hematologia Sp. z o.o. — Clinical Trial Site

89 Registered trials

46 Currently recruiting

Organisation

Pratia Hematologia Sp. z o.o.

Location

Katowice, Poland

Identifier

ORG-100040044

Address

Ul. Tadeusza Kosciuszki 92, 40-519, Poland

Departments

-
#5704 Pratia Onkologia Katowice
#9008: oncology
2141: PRATIA Onkologia Katowice
2806 : Pratia Onkologia Katowice
5702: Hematologia
Hematologia
Hematology
n/a
NA
PL30001:Oncology
Poradnia Onkologiczna
Pratia Onkologia Katowice
Pratia Hematologia Sp. z o.o.
Pratia Onkologia
Pratia Onkologia Katowice
Site name:Pratia Onkologia Katowice, ul. Kosciuszki 92, 40-519 Katowice

Clinical trials at this site (89)

Search interface

A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad… Recruiting

2024-520238-31-01 Advanced Lung Cancer 9 2026-04-20
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting

2025-521692-31-00 Chronic Primary Immune Thrombocytopenia 5 2025-12-19
A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thromb… Recruiting

2024-514401-54-00 Chronic Primary Immune Thrombocytopenia 5 2025-11-13
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting

2024-517184-23-00 platinum-resistant advanced high-grade epithelial ovari 4 2025-10-16
A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting

2024-519928-24-00 Myelodysplastic Syndrome 4 2025-08-21
A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting

2024-518893-15-00 Chronic lymphotic leukemia and Small Lymphocytic lympho 5 2025-07-29
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Metastatic Castration-Resistant Prostate Cancer 5 2025-06-23
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting

2024-515526-89-00 Diffuse Large B-Cell Lymphoma (DLBCL) 4 2025-05-16
A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting

2024-516009-22-00 myelodysplastic neoplasms/syndromes (MDS) 5 2025-04-30
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2025-03-19
An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring Recruiting

2024-515457-21-00 Non-Hodgkin lymphoma and chronic lymphocytic leukemia 3 2024-12-30
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting

2023-505232-36-00 Essential thrombocythemia 5 2024-11-15
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting

2024-513098-31-00 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Ly 4 2024-11-14
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting

2024-511688-27-00 Myelofibrosis 4 2024-09-19
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Recruiting

2022-501697-19-01 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Ly 5 2024-06-18
Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting

2023-504865-21-00 Essential Thrombocythemia patients who have an inadequa 5 2024-04-15
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV… Recruiting

2023-505911-19-00 Acute Myeloid Leukemia 4 2024-01-05
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Multiple myeloma 5 2022-11-14